Follistatin-344: The Myostatin and Activin Ligand Trap — A 2026 Research Guide

Few molecules illustrate the logic of negative regulation as cleanly as follistatin. Where most growth signaling is studied by asking what a ligand does when it binds its receptor, follistatin is studied by asking what happens when a ligand is prevented from binding at all. It is a secreted glycoprotein that physically captures members of the TGF-β superfamily — most notably activin A and myostatin (GDF-8) — before they can assemble a signaling complex. Because myostatin is one of the principal brakes on skeletal-muscle growth, follistatin has become a heavily cited model system for studying the myostatin–activin axis in cell and animal work. The FST344 isoform in particular is the form most often produced recombinantly for laboratory use. This guide summarizes the molecular profile, the receptor- and pathway-level mechanism, and the published preclinical literature as they stand in 2026.

The information below describes in-vitro and preclinical laboratory research only. It is not medical guidance, and none of the findings described here establish safety or efficacy in humans.

Section 1 — Molecular Profile

Follistatin is not a short synthetic peptide but a single-chain glycoprotein, and that distinction matters for how it is characterized. The human FST gene produces two primary isoforms through alternative splicing: FST317 and FST344, containing 317 and 344 amino acid residues in their precursor forms respectively. FST344 is the longer isoform and carries an acidic C-terminal extension that FST317 lacks. After removal of the signal peptide, the FST344 transcript gives rise to the mature circulating species; the widely referenced FS-315 and FS-288 forms arise from downstream processing and proteolysis of this precursor.

Key identifiers used in the literature and in analytical characterization:

• Compound name: Follistatin-344 (FST344, FS-344)
• Gene: FST
• UniProt: P19883 (FST_HUMAN)
• Class: secreted glycoprotein; TGF-β superfamily ligand-binding protein
• Molecular weight: approximately 38 kDa for the recombinant protein (varies with glycosylation and expression system)
• Structural organization: an N-terminal domain (ND) followed by three cysteine-rich follistatin domains, FSD1, FSD2, and FSD3

Because follistatin is a glycoprotein rather than a small molecule, it is not meaningfully described by a single small-molecule CAS number or a compact molecular formula; identity is established instead by sequence, mass, and domain architecture. The first follistatin domain (FSD1) contains a basic, heparin-binding region — the reported sequence around Lys75 through Arg86 — that governs interaction with cell-surface heparan sulfate. That heparin-binding capability is one of the practical features distinguishing the isoforms: it influences whether the protein remains cell-associated or circulates freely, which in turn affects how it behaves in a given assay. Any researcher comparing FST344, FS-315, and FS-288 results should track which isoform was actually used, because their distribution and binding behavior are not identical.

Section 2 — Mechanism

Follistatin is studied as an extracellular antagonist — a ligand trap — and the mechanistic literature is unusually well resolved at the structural level. All of the activity described here is at the pathway and receptor level.

High-affinity ligand capture. Follistatin binds activin A with extremely high affinity, with a reported dissociation constant in the low picomolar range and binding that is effectively irreversible in solution. It binds myostatin (GDF-8) and the related ligand GDF-11 with high, though lower, affinity in the nanomolar range. Structural studies describe two follistatin molecules wrapping around a single ligand dimer in a near-encircling geometry, which is the physical basis for why the interaction is so difficult to reverse.

Receptor occlusion. By enveloping the ligand, follistatin blocks the epitopes that myostatin and activin would otherwise use to recruit their type II and type I serine/threonine kinase receptors — ActRIIA and ActRIIB, together with the type I receptors ALK4 and ALK5. No receptor assembly means no initiation of the intracellular kinase cascade. This is a competitive, stoichiometric mechanism: follistatin does not modify the receptor, it simply removes the ligand from availability.

Downstream SMAD de-repression. In the canonical myostatin pathway, receptor engagement drives phosphorylation of SMAD2 and SMAD3, which then partner with SMAD4 and translocate to the nucleus to enforce a growth-restraining transcriptional program. When follistatin sequesters myostatin, SMAD2/3 phosphorylation is reduced, and the brake this pathway imposes on muscle-associated signaling is lifted in the model system under study. In cultured myoblasts this de-repression has been linked to satellite-cell proliferation and to mTOR-associated signaling.

Throughout the literature these are described as mechanisms follistatin has been studied for and researched for in defined experimental systems — activin and myostatin neutralization, SMAD-pathway antagonism — not as demonstrated clinical effects in humans.

Section 3 — Preclinical Research Data

The follistatin preclinical dataset is large and spans cell culture, rodent genetics, and larger-animal gene-delivery work. Several themes recur.

In cell-based systems, recombinant follistatin is a standard reagent for neutralizing activin or myostatin in SMAD reporter assays, typically applied in the tens-to-hundreds of nanograms-per-milliliter range to suppress ligand-driven signaling. This makes it a workhorse negative control in TGF-β signaling experiments quite apart from any muscle-specific interest.

In rodent work, follistatin overexpression has been characterized as a driver of skeletal-muscle hypertrophy, with reported increases in muscle weight on the order of tens of percent in control animals; studies using irradiation to blunt satellite-cell proliferation showed a smaller effect, which is one of the lines of evidence implicating cell proliferation in the response. Genetic studies dissecting the pathway have also shown that follistatin-mediated hypertrophy depends on SMAD3 and mTOR signaling and can occur partly independently of myostatin itself, indicating that activin neutralization contributes alongside myostatin neutralization.

In larger animals, gene-delivery studies remain the most-cited proof-of-concept work, reporting measurable increases in muscle mass and strength in nonhuman primates after localized delivery of a follistatin-expressing vector, and describing the intervention as well tolerated in those preclinical models. None of these datasets constitute evidence of a therapeutic effect in humans; they describe measured changes in defined in-vitro and animal systems, which is the correct frame for interpreting them.

Section 4 — Published Literature

The following are real, published papers that anchor the follistatin research record. Researchers should consult the primary sources directly rather than relying on summaries.

• Nakamura T, et al. (1990). “Activin-binding protein from rat ovary is follistatin.” Science 247(4944):836–838. The identification of follistatin as an activin-binding protein.
• Lee SJ, McPherron AC (2001). “Regulation of myostatin activity and muscle growth.” PNAS 98(16):9306–9311. Establishes follistatin as an antagonist of myostatin in vivo.
• Amthor H, et al. (2004). “Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis.” Developmental Biology 270(1):19–30.
• Schneyer AL, et al. (2008). “Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin.” Endocrinology 149(9):4589–4595.
• Cash JN, et al. (2009). “The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding.” EMBO Journal 28(17):2662–2676. The structural basis of the ligand-trap mechanism.
• Gilson H, et al. (2009). “Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin.” American Journal of Physiology — Endocrinology and Metabolism 297(1):E157–E164.
• Kota J, et al. (2009). “Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.” Science Translational Medicine 1(6):6ra15.
• Winbanks CE, et al. (2012). “Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin.” Journal of Cell Biology 197(7):997–1008.

Together these span the discovery of follistatin’s activin-binding role, the structural mechanism of ligand capture, the cellular basis of the hypertrophy response, and the pathway dependencies that separate the myostatin and activin contributions. They are the citations most worth reading in full before designing new experiments.

Section 5 — Research Applications

In laboratory settings, follistatin-344 is used chiefly as a tool reagent for interrogating TGF-β superfamily signaling. Reported in-vitro applications include serving as a neutralizing agent in activin- and myostatin-driven SMAD2/3 reporter assays; acting as a comparator in structural and binding studies of ligand-trap geometry; and functioning as a reference antagonist in myoblast and satellite-cell proliferation models. In animal research it appears most often as a gene-delivery payload or overexpression construct in studies of the myostatin–activin axis.

Because the isoforms differ meaningfully, careful documentation of which form — FST344, FS-315, or FS-288 — was used, at what concentration, and at what purity is essential to reproducibility. The heparin-binding behavior of FST344 in particular means that its cell-surface localization can differ from the shorter isoforms, so results are not always directly transferable between them. Recombinant follistatin is typically supplied as a lyophilized powder and is sensitive to storage conditions; the literature and vendor documentation generally recommend storage at −20°C, protection from light and moisture, and reconstitution in an appropriate buffer with stock concentrations verified rather than assumed.

The expression system is another variable worth recording. Follistatin produced in mammalian systems is glycosylated and runs at a higher apparent molecular weight than material produced in bacterial systems, and glycosylation state can influence both stability and binding kinetics. For any project comparing results across sources, the expression host is part of the material’s identity, not a footnote.

Section 6 — How to Evaluate a Source

Protein characterization is only as good as the analytical data behind it, and for a research-grade glycoprotein the certificate of analysis (COA) is the document that matters most. When evaluating any follistatin-344 source, a researcher should confirm:

• Identity by mass spectrometry (LC-MS) and by SDS-PAGE, confirming the expected apparent molecular weight (~38 kDa for glycosylated recombinant material) and distinguishing FST344 from the shorter FS-315 and FS-288 isoforms.
• Purity by HPLC, with a stated percentage and a visible chromatogram rather than a bare number.
• Endotoxin testing (USP <85> LAL), which is critical for any cell-based work, since endotoxin contamination independently activates inflammatory signaling and can confound TGF-β assays.
• Heavy metals by ICP-MS.
• Lot-specificity: the COA should correspond to the exact batch shipped, be dated, and name the accredited laboratory that performed the testing.

A supplier that cannot produce a lot-matched COA naming its testing lab has not given you enough to trust the material. As a pricing reference point, recombinant follistatin-344 in the research market is commonly listed in 1 mg lyophilized vials, with per-milligram cost varying widely by purity grade, expression system, and vendor — but price should never substitute for analytical verification. A high-purity, endotoxin-tested, mammalian-expressed preparation and a cheap bacterial preparation are not interchangeable, and the COA is where that difference becomes visible.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

Founding batches are documented end to end, and full analytical data files are available per lot. You can review current documentation in the COA library, read the underlying methodology on the verification standard page, see the follistatin-344 listing, or browse the full catalog in the shop.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.